Schizophrenia example

While the obvious value of in vivo animal models is clear, there also are instances—especially in cases of inflammatory arthritis, behavior, and tumor growth—where they have failed to be predictive of useful clinical activity in humans [51], For example, leukotriene (LTB4) antagonists showed activity in animal models of inflammatory arthritis yet failed to be useful in rheumatoid arthritis [52]. Similarly, dopamine D4 antagonists showed activity in animal behavior models previously predictive of dopamine D2 antagonists in schizophrenia. However, testing of dopamine D4 antagonists showed no efficacy in humans [53]. 

A related issue is the question of which patients to include in an evaluation. The most usefirl evaluation would be one that included all patients likely to use a service in the real world. However, in order to make evaluations feasible, and because of the need to achieve the informed consent of patients, many prospective clinical trials exclude certain patient groups. For example, many schizophrenia trials exclude patients with... 

A number of azetidine-based compounds have been disclosed in patent applications from Aventis Pharma for CBi-modulated treatment of diseases such as obesity, Parkinson s disease, schizophrenia, respiratory and neurological diseases [330-334]. Compound (556) was specifically claimed for use in two formulation patent applications [330, 331] for a stable semi-solid composition and oral emulsion composition, respectively. The optional coadministration of an agent that activates norepinephrinergic and se-rotoninergic neurotransmission (for example, sibutramine) or dopaminergic neurotransmission was also claimed for the treatment of obesity. The optional use of a dopamine agonist (for example, levodopa) was claimed... 

Patients tend to believe that medications from nature are non-toxic, non-addicted, and non-invasive. Therefore complementary medicines are usually used in common, less severe, and chronic mental disorders such as sleep disorders, neurasthenia, and anxiety disorders. It is also applied in incurable conditions, for example dementias, autism, and schizophrenia, when doctors and families have tried desperately all means and finally turned to complementary medicine as the last hope. 

A few illustrative examples of important agrochemicals and pharmaceuticals that contain a CF3 group are given in Fig. 5.1. They include the insecticide triflumuron (5-1), the neuroleptic fluphenazene (5-2), which is used in the treatment of schizophrenia, and the well-known antidepressant drug, PROZAC (5-3). 

Schizophrenia and its Pharmacotherapy An Example of Major Mental Illness... 

Since then, several potent and selective sarcosine-based inhibitors have been reported in the literature. Representative examples include 5 (LY2365109) [37,38], 6 ((R)-N[3-phenyl-3-(4 -(4-toluoyl)phenoxy)-propyl] sarcosine or (R)-NPTS) [39,40], 7 [41], 8 [42], 9 (JNJ-17305600) [43], and 10 [44]. Members of these series have demonstrated efficacy in several psychosis models [38,40] and JNJ-17305600 is reportedly in Phase I clinical trials for schizophrenia (data not available) [23]. 

Dopamine receptor blocking agents. Many of the neuroleptics used in the treatment of schizophrenia frequently produce parkinsonian symptoms as unwanted effects. Neuroleptics block dopamine receptors and their therapeutic effect seems to be related to this action. Although these drugs act on DA systems without distinction, some are more selective. Thioridazine, clozapine and molindone, for example, have electrophysiological effects in the limbic region of the brain but little action in the nigro-striatal area. This selectivity may be related to receptor subtype specificity (see Chs 12 and 54). 

Mental disorders, for example, multiple subtypes of anxiety, chronic fatigue syndrome, depression, sometimes together with chronic pain, posttraumatic stress disorders (PTSD), and schizophrenia... 

A variety of kinds of evidence have linked emotional behavior to hormones. Two conditions, the menstrual cycle and menopause, have been the focus of a great deal of research on human behavior. In addition, gender differences in the prevalence of mental illnesses have been used as indirect evidence for possible hormonal effects on emotional disorders. For example, depression is more common in women than in men. In contrast, a pubertal onset of schizophrenia is more common in males than females (Hafner, et al., 1993), although the lifetime occurrence of schizophrenia is approximately equal in men and women (Seeman, 1996). Effects of hormones on emotional lability in men are described above in the context of aggression. 

If individuals differ at birth in their susceptibility to schizophrenia, for example, of what does their differentness consist Aside from anatomical differences with respect to brain and endocrine glands especially, there is the possibility that they differ in their nutritional requirements. One may have need, in order to meet the stresses of life and keep his brain metabolism functioning, of a larger amount of certain crucial nutrients than the other. Lacking these nutrients, his brain metabolism gets out of joint and mental disease results. 

Many DA receptor antagonists (neuroleptics) for treating psychoses (for example, schizophrenia) have become efficient medicines. However, most of them induce severe extrapyramidal side-effects (EPS) akin to parkinsonian symptoms and also, more seriously, they induce tardive dyskinesias (TD). There is a need for improvements in the neuroleptics in the clinic. The substituted benzamides are D2 antagonists, some of which display a high degree of limbic selectivity. Such a regional selectivity has been suggested to be beneficial from the side-effects point of view [11,12]. 

BZ is undeniably psychotomimetic, but only in the broad sense that it causes a true loss of contact with reality. It also lacks most of the distinguishing features of the natural psychoses. Schizophrenia, for example, rarely produces visual hallucinations. BZ, on the other hand, seldom produces well-organized delusions (as may occur with LSD). BZ does not produce persistent social withdrawal, as seen in chronic schizophrenia, nor does it create the annoying overfriendliness of the manic phase of bipolar disorder. 

By contrast, studies of the dopamine D -like receptors have found evidence for the association of the receptor with disease (66) these studies have been replicated (41,42). From among the multitude of these studies, only selected examples are reviewed here. For example, evidence both for and against the association of the dopamine D -like receptors with schizophrenia has been reported. Polymorphisms of the dopamine receptor, including the third intracellular loop VNTR, alter dopamine receptor expression. In addition to association with schizophrenia (3,67-70), the dopamine polymorphisms have been associated with the genetic basis of the variable efficacy of antipsychotics such as clozapine (or neuromuscular toxicity—tardive dyskinesia) (69,71,72). Similarly, promoter SNPs have been associated with altered clozapine efficacy (67,68,73). 

---